Cargando…

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for hematologic malignancies, however, response rates and associated immune-related adverse effects widely vary among patients. Here we show, by comparing diversity and composition of the gut microbiome during dif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yongxian, Li, Jingjing, Ni, Fang, Yang, Zhongli, Gui, Xiaohua, Bao, Zhiwei, Zhao, Houli, Wei, Guoqing, Wang, Yiyun, Zhang, Mingming, Hong, Ruimin, Wang, Linqin, Wu, Wenjun, Mohty, Mohamad, Nagler, Arnon, Chang, Alex H., van den Brink, Marcel R. M., Li, Ming D., Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461447/ https://www.ncbi.nlm.nih.gov/pubmed/36085303 http://dx.doi.org/10.1038/s41467-022-32960-3

Ejemplares similares

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Wang, Linqin, et al.
Publicado: (2021)

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Wang, Yiyun, et al.
Publicado: (2021)

Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment
por: Zhou, Linghui, et al.
Publicado: (2021)

Clinical Hematology International: Why a New Journal in Hematology?
por: Mohty, Mohamad, et al.
Publicado: (2019)

COVID-19 in Hematologic Malignancies: Big Challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

Looking Ahead: Clinical Hematology International Turns One
por: Mohty, Mohamad, et al.
Publicado: (2020)

Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
por: Mohty, Mohamad, et al.
Publicado: (2020)

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma
por: Hong, Ruimin, et al.
Publicado: (2021)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
por: Ding, Shuyi, et al.
Publicado: (2023)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
por: Zhao, Houli, et al.
Publicado: (2020)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunobiology and Pharmacologic Manipulation of Dendritic and Regulatory Cells
por: Mohty, Mohamad, et al.
Publicado: (2013)

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
por: Xu, Xueer, et al.
Publicado: (2023)

Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study
por: Hu, Yongxian, et al.
Publicado: (2023)

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT
por: Munker, Reinhold, et al.
Publicado: (2017)

Another Year to Celebrate Advances in Clinical Hematology
por: Mohty, Mohamad, et al.
Publicado: (2023)

The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia
por: Czyz, Anna, et al.
Publicado: (2019)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
por: Zhou, Linghui, et al.
Publicado: (2021)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Weathering the storm: COVID-19 infection in patients with hematological malignancies
por: Wang, Lin-qin, et al.
Publicado: (2020)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Liu, Yadan, et al.
Publicado: (2021)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

CAR-T cell therapy for hematological malignancies: History, status and promise
por: Wang, Chao, et al.
Publicado: (2023)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_esctdgb76n004b5g1u55aqd7tc